Mechanisms of PTEN loss in cancer: it’s all about diversity

Virginia Álvarez-Garcia, Yasmine Tawil, Helen M. Wise, Nicholas R. Leslie

Research output: Contribution to journalArticle

22 Citations (Scopus)
10 Downloads (Pure)

Abstract

PTEN is a phosphatase which metabolises PIP 3 , the lipid product of PI 3-Kinase, directly opposing the activation of the oncogenic PI3K/AKT/mTOR signalling network. Accordingly, loss of function of the PTEN tumour suppressor is one of the most common events observed in many types of cancer. Although the mechanisms by which PTEN function is disrupted are diverse, the most frequently observed events are deletion of a single gene copy of PTEN and gene silencing, usually observed in tumours with little or no PTEN protein detectable by immunohistochemistry. Accordingly, with the exceptions of glioblastoma and endometrial cancer, mutations of the PTEN coding sequence are uncommon (<10%) in most types of cancer. Here we review the data relating to PTEN loss in seven common tumour types and discuss mechanisms of PTEN regulation, some of which appear to contribute to reduced PTEN protein levels in cancers.

Original languageEnglish
Pages (from-to)66-79
Number of pages14
JournalSeminars in Cancer Biology
Volume59
Early online date7 Feb 2019
DOIs
Publication statusPublished - Dec 2019

Keywords

  • Cancer
  • Mutation
  • PI 3-Kinase
  • PTEN
  • Tumour suppressor

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Mechanisms of PTEN loss in cancer: it’s all about diversity'. Together they form a unique fingerprint.

  • Cite this